Swiss pharma giant Novartis (NOVN: VX) has announced positive Phase III results showing the efficacy of its BAF312 (siponimod) candidate in secondary progressive multiple sclerosis (SPMS).
The drug met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo in the Phase III EXPAND trial, the largest randomized, controlled study in SPMS to date.
There are currently very limited treatment options for SPMS, a form of multiple sclerosis associated with gradual worsening of symptoms and accumulation of disability, independent of relapses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze